Retatrutide vs tirzepatide

Retatrutide activates GIP, GLP-1 and glucagon receptors; tirzepatide activates GIP and GLP-1 receptors. Both have substantial placebo-controlled weight-loss results, but the trials differ in duration, population and analysis. Retatrutide remains investigational in October 2026, and the registered direct TRIUMPH-5 comparison has no outcome result in the accessed official listing.

Research reviewed October 15, 2026. Educational information only.

Two overlapping receptor strategies

Retatrutide is one peptide acting at the receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1 (GLP-1) and glucagon. Tirzepatide is one peptide acting at GIP and GLP-1 receptors. Both use hormone systems involved in appetite and glucose regulation. Retatrutide adds glucagon-receptor activity, but counting receptors cannot establish the relative clinical contribution of that activity.

The clearest comparison therefore begins with people and measured outcomes. TRIUMPH-1 tested retatrutide against placebo in adults with obesity without diabetes. SURMOUNT-1 tested tirzepatide against placebo in adults without diabetes who had obesity, or overweight with a weight-related complication. Their reported averages describe different randomized experiments.

The main differences

The published 2026 retatrutide result

TRIUMPH-1 randomized 2,339 adults to retatrutide or placebo for 80 weeks, with healthy-diet and physical-activity support in the program. Average weight fell 17.6%, 23.7% and 25.0% across the three assigned retatrutide groups and 3.9% with placebo. The two higher groups were the primary comparisons and had adjusted additional weight reductions of 19.8 and 21.0 percentage points, respectively (P<0.001 for both).

The paper’s weight estimate follows the treatment-regimen approach, including events such as treatment discontinuation in the effect of assignment. Lilly’s earlier 28.3% headline for the highest group used an efficacy analysis assuming continued treatment. These are different estimates from the same trial, not conflicting independent trials. Pairing the 28.3% figure with a treatment-regimen result from another medicine would introduce an additional analysis mismatch.

A separate trial, TRIUMPH-2, enrolled 1,152 adults with obesity and type 2 diabetes. At 80 weeks, weight fell 11.9%, 16.8% and 18.8% with retatrutide versus 5.1% with placebo under its treatment-regimen analysis. Most participants (1,055 of 1,152) were already taking oral glucose-lowering medicines. The highest group’s adjusted additional loss was 13.8 percentage points (95% CI 11.8–15.8). This is a different population from TRIUMPH-1 and cannot be used to isolate diabetes itself as the cause of a smaller average response.

The tirzepatide result and the direct trial still awaited

SURMOUNT-1 randomized 2,539 adults without diabetes to tirzepatide or placebo alongside lifestyle intervention for 72 weeks. Average weight reductions were 15.0%, 19.5% and 20.9% across the active groups, versus 3.1% with placebo. In the highest group, the mean reduction was 20.9% (95% CI 19.9–21.8). The main treatment-regimen analysis assessed effects regardless of treatment discontinuation.

The largest published retatrutide average is numerically larger than the largest SURMOUNT-1 average, but subtracting them does not estimate a retatrutide-versus-tirzepatide effect. Follow-up differs by eight weeks, and trial populations, exposure protocols and missing-data handling may also affect the estimates. Each medicine’s placebo-controlled result remains informative without ranking the medicines.

The official TRIUMPH-5 listing identifies the experiment intended to answer that direct question. It compares retatrutide with tirzepatide in adults with obesity, has an enrollment goal of 800 and lists dates through December 2026. No comparative outcome appears in the accessed official material as of October 15. A registration establishes the planned comparison, not which treatment performed better.

Long blood persistence does not rank weight loss

A 12-week phase 1b study in adults with type 2 diabetes estimated retatrutide’s elimination half-life at approximately six days after subcutaneous administration. Its safety population included 72 people across retatrutide, placebo and dulaglutide groups. This was an early dose-ranging study, and 29 participants discontinued the study prematurely; it cannot substitute for the larger efficacy trials.

The current Zepbound label reports an elimination half-life of approximately five to six days in people with overweight or obesity, and in obesity with sleep apnea. These estimates indicate slow removal of the respective peptides from circulation. Similar half-lives do not mean identical receptor activity, tolerability or weight outcomes, and they provide no justification for combining the compounds.

Digestive symptoms and other safety findings

In SURMOUNT-1, the most common tirzepatide adverse events were gastrointestinal and were generally mild or moderate, particularly during escalation. Adverse events caused treatment stopping in 4.3%, 7.1% and 6.2% of the active groups, versus 2.6% with placebo. The current product label also addresses severe gastrointestinal reactions, kidney injury from dehydration, gallbladder disease, pancreatitis, hypoglycemia with certain diabetes medicines and aspiration around anesthesia. Its boxed thyroid-tumor warning comes from animal findings, with human relevance uncertain.

Retatrutide’s published TRIUMPH-1 abstract identifies gastrointestinal events as most common but does not provide a complete safety table. The separate TRIUMPH-2 abstract gives more detail: in the highest group, diarrhea occurred in 96 of 286 treated participants (34%) versus 38 of 287 (13%) with placebo, and nausea in 28% versus 8%. Low blood pressure and dysesthesia, meaning altered or unpleasant skin sensations, were also more frequent. In the highest retatrutide group, 8% of participants permanently stopped treatment because of adverse events or died, compared with 5% given placebo. Investigators judged the reported deaths unrelated to study treatment.

Those percentages come from different trials with different diabetes status and background medicines. They cannot establish that either agent is safer. Retatrutide remains investigational, and the lack of an approved label leaves its eventual benefit-risk assessment unresolved.

What the comparison can establish today

The evidence now includes published phase 3 retatrutide weight outcomes, so describing it only as a phase 2 candidate is outdated. It remains an investigational drug, while tirzepatide has approved products; Zepbound’s current indications include long-term weight management in the specified adult population and moderate-to-severe obstructive sleep apnea with obesity. Approval and the number of receptors answer different questions from comparative efficacy.

For the present comparison, the defensible conclusion is that both produced greater weight loss than placebo in their own trials. A direct superiority conclusion needs the direct randomized result and its uncertainty. The retatrutide profile, tirzepatide profile and retatrutide versus semaglutide essay give additional trial and product context.

Frequently asked questions

Profiles and related reading

References

1. Jastreboff AM, Kaplan LM, Davies MJ, Wilding JPH, Ahmad NN, Murray M, Du Y, Makarova N, Giblin K, Schloot NC, Wang Y, TRIUMPH-1 Investigators. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. The New England journal of medicine. 2026. doi:10.1056/NEJMoa2604169. PMID:42814954.

   TRIUMPH-1 randomized 2339 adults with obesity without diabetes. At 80 weeks, mean weight reductions ranged 17.6–25.0% with retatrutide versus 3.9% with placebo using the treatment-regimen analysis.

2. Bellido V, le Roux CW, Ekinci EI, Bjornstad P, Frias JP, Giblin K, Eyde S, Park SY, Ferro J, Johnson C, Taylor A. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet (London, England). 2026;408(10563):1455–1472. doi:10.1016/S0140-6736(26)01861-1. PMID:42810372.

   In TRIUMPH-2, 1152 adults with obesity and type 2 diabetes were randomized to retatrutide or placebo. Weight fell more with retatrutide at 80 weeks; digestive events, low blood pressure and altered skin sensations were more frequent.

3. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A, SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. The New England journal of medicine. 2022;387(3):205–216. doi:10.1056/NEJMoa2206038. PMID:35658024.

   SURMOUNT-1 randomized 2539 adults without diabetes to tirzepatide or placebo. Mean weight fell 15.0–20.9% versus 3.1% at 72 weeks using an analysis including treatment discontinuation; digestive symptoms were common.

4. Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, Haupt A, Benson CT, Hernandez-Illas M, D'Alessio DA, Milicevic Z. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet (London, England). 2022;400(10366):1869–1881. doi:10.1016/S0140-6736(22)02033-5. PMID:36354040.

   The 12-week phase 1b trial in type 2 diabetes estimated a retatrutide half-life of approximately six days. The 72-person safety population included 52 retatrutide, 15 placebo and five dulaglutide recipients.

5. Eli Lilly and Company. What to know about retatrutide. Manufacturer development-status information; accessed October 15, 2026.

   The manufacturer identifies retatrutide as investigational and not approved by any regulatory agency, despite completed phase 3 reports.

6. Eli Lilly and Company. A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity (TRIUMPH-5). Sponsor trial listing, J1I-MC-GZBP; ClinicalTrials.gov NCT06662383. Accessed October 15, 2026.

   TRIUMPH-5 is designed to compare retatrutide directly with tirzepatide in adults with obesity. The official listing describes an 800-person enrollment goal and dates through December 2026; it posts no comparative outcome in the accessed material.

7. Giblin K, Kaplan LM, Somers VK, Le Roux CW, Hunter DJ, Wu Q, Lalonde A, Ahmad N, Bethel MA. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes, Obesity and Metabolism. 2026;28(1):83–93. doi:10.1111/dom.70209. PMID:41090431.

   The design report explains that TRIUMPH used healthy-diet and physical-activity support and nested disease-specific assessments within selected obesity trials. It reports design, not new efficacy results.

8. Eli Lilly and Company. Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. May 21, 2026. Sponsor announcement.

   The sponsor’s 28.3% headline uses an efficacy analysis assuming continued treatment. It differs from the 25.0% treatment-regimen estimate subsequently reported in the published TRIUMPH-1 abstract.

9. Eli Lilly and Company. ZEPBOUND (tirzepatide) injection: U.S. prescribing information. Revised August 2026. DailyMed; accessed October 15, 2026.

   Tirzepatide activates GIP and GLP-1 receptors. Zepbound is indicated for long-term adult weight management in its specified population and moderate-to-severe sleep apnea with obesity; the label describes approximately 5–6 day elimination and material safety warnings.